{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:41:57Z","timestamp":1787611317969,"version":"build-2736575974"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM23\/00174"],"award-info":[{"award-number":["CM23\/00174"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI22\/00262"],"award-info":[{"award-number":["FI22\/00262"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01046"],"award-info":[{"award-number":["PI21\/01046"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Organising pneumonia is an interstitial lung disease linked to infections and other conditions. Cryptogenic organising pneumonia is a rarer, idiopathic form. Organising pneumonia has become one of the most frequent respiratory complications following severe acute respiratory syndrome coronavirus 2 pneumonia. Standard treatment involves the use of glucocorticoids. The objective of the study is to determine the optimal dosage of oral corticosteroids for the treatment of this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Randomised, open-label, assessor-blinded, parallel-group, single-centre, noninferiority clinical trial with an active control group comparing two oral prednisone regimens. The control group received prednisone 0.75\u2005mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 4\u2005weeks; 0.5\u2005mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 4\u2005weeks; 20\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 4\u2005weeks; 10\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 6\u2005weeks; or 5\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 6\u2005weeks (total treatment duration 6\u2005months) and the experimental group prednisone 0.5\u2005mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 3\u2005weeks; 20\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 3\u2005weeks; 15\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 2\u2005weeks; 10\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 2\u2005weeks; and 5\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      for 2\u2005weeks (total treatment duration 3\u2005months). Visits were carried out at baseline and at 3, 6 and 12\u2005months, recording clinical history, physical examination, pulmonary function tests and chest computed tomography. The primary outcome was noninferiority with a margin of 10% in diffusing capacity of the lung for carbon monoxide (\n                      <jats:italic>D<\/jats:italic>\n                      <jats:sub>LCO<\/jats:sub>\n                      ) at 6\u2005months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      79 patients were randomised according to intention-to-treat group, 40 to the experimental group and 39 to the control group. Mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      baseline\n                      <jats:italic>D<\/jats:italic>\n                      <jats:sub>LCO<\/jats:sub>\n                      was 59.3\u00b116.7% in the experimental group and 55.5\u00b116.5% in the control group, with mean improvements at 6\u2005months of 11.7% (95% CI 7.18\u201316.17%) and 12.8% (95% CI 8.57\u201317.11%) respectively. The difference between groups at 6\u2005months was 1.23% (95% CI \u22125.13\u20137.59%), the experimental regimen being noninferior to the control group with the margin of 10%. Patients in the experimental group had fewer than half as many adverse effects as controls: nine (23%)\n                      <jats:italic>versus<\/jats:italic>\n                      22 (56%) (p=0.0027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with oral corticosteroids lasting 3 months (initial dose of prednisone 0.5\u2005mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) may be recommended in patients with post-COVID organising pneumonia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01552-2025","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:38:48Z","timestamp":1778769528000},"page":"01552-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral corticosteroid dosing strategies for post-COVID-19 organising pneumonia: NORCOVID clinical trial"],"prefix":"10.1183","volume":"12","author":[{"given":"David","family":"Espejo-Castellanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Gonz\u00e1lez-Amezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2880-4019","authenticated-orcid":false,"given":"Mar\u00eda-Florencia","family":"Pilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antia","family":"Ferreiro-Posse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galo","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Romero-Mesones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-5772","authenticated-orcid":false,"given":"I\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-8442","authenticated-orcid":false,"given":"Maria A.","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jes\u00fas","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-7913","authenticated-orcid":false,"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Se-COVID-19 team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Arjona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Barrecheguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Berastegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clofent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angeles","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeisson","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Pallero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Revilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sa\u00e9z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026082403352697000_12.4.01552-2025.1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMra2116777","article-title":"Cryptogenic organizing pneumonia","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082403352697000_12.4.01552-2025.2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.chest.2021.12.659","article-title":"Algorithmic approach to the diagnosis of organizing pneumonia: a correlation of clinical, radiologic, and pathologic features","volume":"162","author":"Cherian","year":"2022","journal-title":"Chest"},{"key":"2026082403352697000_12.4.01552-2025.3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.21037\/atm-20-4490","article-title":"Analysis of the clinical characteristics of 176 patients with pathologically confirmed cryptogenic organizing pneumonia","volume":"8","author":"Zhang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026082403352697000_12.4.01552-2025.4","first-page":"129","article-title":"Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients","volume":"35","author":"Vieira","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026082403352697000_12.4.01552-2025.5","doi-asserted-by":"crossref","first-page":"e0240347","DOI":"10.1371\/journal.pone.0240347","article-title":"Organizing pneumonia of COVID-19: time-dependent evolution and outcome in CT findings","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"2026082403352697000_12.4.01552-2025.6","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3390\/cells12182238","article-title":"Pulmonary sequelae of COVID-19: focus on interstitial lung disease","volume":"12","author":"Johnston","year":"2023","journal-title":"Cells"},{"key":"2026082403352697000_12.4.01552-2025.7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.chest.2021.09.016","article-title":"Histological findings in transbronchial cryobiopsies obtained from patients after COVID-19","volume":"161","author":"Culebras","year":"2022","journal-title":"Chest"},{"key":"2026082403352697000_12.4.01552-2025.8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216088"},{"key":"2026082403352697000_12.4.01552-2025.9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1325157"},{"key":"2026082403352697000_12.4.01552-2025.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"2026082403352697000_12.4.01552-2025.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2026082403352697000_12.4.01552-2025.12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016. European Medicines Agency. Date last accessed: 9 December 2024. www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice-scientific-guideline#external-links-17996"},{"key":"2026082403352697000_12.4.01552-2025.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-11-201006010-00232"},{"key":"2026082403352697000_12.4.01552-2025.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.8.545"},{"key":"2026082403352697000_12.4.01552-2025.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02930-2021"},{"key":"2026082403352697000_12.4.01552-2025.16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218275"},{"key":"2026082403352697000_12.4.01552-2025.17","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02163-x"},{"key":"2026082403352697000_12.4.01552-2025.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9909015"},{"key":"2026082403352697000_12.4.01552-2025.19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12890-018-0764-8","article-title":"Predictive factors for relapse of cryptogenic organizing pneumonia","volume":"19","author":"Saito","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026082403352697000_12.4.01552-2025.20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4046\/trd.2015.78.3.190","article-title":"Predictors of relapse in patients with organizing pneumonia","volume":"78","author":"Kim","year":"2015","journal-title":"Tuberc Respir Dis"},{"key":"2026082403352697000_12.4.01552-2025.21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1378\/chest.102.1_Supplement.21S","article-title":"Clinical features of BOOP in Japan","volume":"102","author":"Yamamoto","year":"1992","journal-title":"Chest"},{"key":"2026082403352697000_12.4.01552-2025.22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.arbres.2021.03.018","article-title":"Different faces of idiopathic pulmonary fibrosis with preserved forced vital capacity","volume":"58","author":"Bermudo","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026082403352697000_12.4.01552-2025.23","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082403352697000_12.4.01552-2025.24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.arbres.2019.08.019","article-title":"An open-label study with pirfenidone on chronic hypersensitivity pneumonitis","volume":"56","author":"Mateos-Toledo","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"2026082403352697000_12.4.01552-2025.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001563"},{"key":"2026082403352697000_12.4.01552-2025.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001580"},{"key":"2026082403352697000_12.4.01552-2025.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026082403352697000_12.4.01552-2025.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811737"},{"key":"2026082403352697000_12.4.01552-2025.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2026082403352697000_12.4.01552-2025.30","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202008-1002OC"},{"key":"2026082403352697000_12.4.01552-2025.31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(21)00174-0","article-title":"3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study","volume":"9","author":"Wu","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026082403352697000_12.4.01552-2025.32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3390\/tomography8030097","article-title":"Follow-up CT patterns of residual lung abnormalities in severe COVID-19 pneumonia survivors: a multicenter retrospective study","volume":"8","author":"Besutti","year":"2022","journal-title":"Tomography"},{"key":"2026082403352697000_12.4.01552-2025.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01552-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:35:34Z","timestamp":1787567734000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01552-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.01552-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01552-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}